专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

CA2597596C LIQUID FORMULATIONS OF RAPAMYCIN FOR INTRAOCULAR DELIVERY 未知
公开(公告)号：CA2597596C
公开(公告)日：2014-09-09
申请号：CA2597596
申请日：2006-02-09
申请人： MACUSIGHT INC
发明人： MUDUMBA SREENIVASU , DOR PHILIPPE J M , NIVAGGIOLI THIERRY , WEBER DAVID A , FAROOQ SIDIQ MOHAMMED
IPC分类号： A61K31/44
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non- dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.

2. 发明专利

BRPI0609432A2 未知
公开(公告)号：BRPI0609432A2
公开(公告)日：2010-04-06
申请号：BRPI0609432
申请日：2006-03-21
申请人： MACUSIGHT INC
发明人： MUDUMBA SREENIVASU , DOR PHILIPPE J M , WEBER DAVID A , FAROOQ SIDIQ MOHAMMED , NIVAGGIOLI THIERRY
IPC分类号： A61K31/436 , A61K9/00 , A61P27/02
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are solid drug delivery systems and methods for providing extended delivery of therapeutic agents to such tissues. A solid drug delivery system may be placed in a subject, including but not limited to placement between the sclera and the conjunctiva or transscleral placement. Described methods may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, age-related macular degeneration, or wet age-related macular degeneration in a subject. The solid drug delivery devices may comprise rapamycin or other therapeutic agents. Also described are methods of treating ocular diseases or disorders by administering an antiproliferative agent, including but not limited to rapamycin, proximal to an ocular device.

3. 发明专利

CA2602525A1 DRUG DELIVERY SYSTEMS FOR TREATMENT OF DISEASES OR CONDITIONS 未知
公开(公告)号：CA2602525A1
公开(公告)日：2006-09-28
申请号：CA2602525
申请日：2006-03-21
申请人： MACUSIGHT INC
发明人： FAROOQ SIDIQ , NIVAGGIOLI THIERRY , WEBER DAVID A , MUDUMBA SREENIVASU , DOR PHILIPPE J M
IPC分类号： A61K31/436 , A61K9/00 , A61P27/02
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are solid drug delivery systems and methods for providing extended delivery of therapeutic agents to such tissues. A solid drug delivery system may be placed in a subject, including but not limited to placement between the sclera and the conjunctiva or transscleral placement. Described methods may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, age-related macular degeneration, or wet age-related macular degeneration in a subject. The solid drug delivery devices may comprise rapamycin or other therapeutic agents. Also described are methods of treating ocular diseases or disorders by administering an antiproliferative agent, including but not limited to rapamycin, proximal to an ocular device.

4. 发明专利

CA2539324A1 TRANSSCLERAL DELIVERY 未知
公开(公告)号：CA2539324A1
公开(公告)日：2005-03-31
申请号：CA2539324
申请日：2004-09-20
申请人： MACUSIGHT INC
发明人： COOPER EUGENE R , KLEINMAN DAVID M , NIVAGGIOLI THIERRY , DOR PHILIPPE J M , MUDUMBA SREENIVASU
IPC分类号： A61K31/436 , A61K9/00
摘要： Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecti ng solutions or suspensions adjacent to or within the sclera and implanting sol id structures containing the therapeutic agent adjacent to or within the sclera . These methods may be used for administering rapamycin or related compounds t o treat choroidal neovascularization associated with age-related macular degeneration.

5. 发明专利

CA2597596A1 LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS 未知
公开(公告)号：CA2597596A1
公开(公告)日：2006-08-17
申请号：CA2597596
申请日：2006-02-09
申请人： MACUSIGHT INC
发明人： FAROOQ SIDIQ MOHAMMED , NIVAGGIOLI THIERRY , MUDUMBA SREENIVASU , DOR PHILIPPE J M , WEBER DAVID A
IPC分类号： A61K31/44
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.

6. 发明专利

CA2597590A1 FORMULATIONS FOR OCULAR TREATMENT 未知
公开(公告)号：CA2597590A1
公开(公告)日：2006-08-17
申请号：CA2597590
申请日：2006-02-09
申请人： MACUSIGHT INC
发明人： WEBER DAVID A , NIVAGGIOLI THIERRY , MUDUMBA SREENIVASU , DOR PHILIPPE J M
IPC分类号： A61K31/44
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式